The proposed statewide inventory program would track AFFF stocks across Maine and start collecting data in July 2026, while a takeback program, set for 2027, aims to safely dispose of remaining foam
If you choose to stop the injections, maintaining a healthy lifestyle remains essential to preserving your results
Gastrointestinal adverse events including nausea, vomiting, and diarrhea are common with current GLP-1 agonists, leading some patients to discontinue treatment or fail to reach maximally effective doses
Understanding GLP-1 Medications What are GLP-1 Medications
While occasional muscle cramps are common and often benign, persistent or severe cramping may indicate electrolyte imbalances, peripheral neuropathy, or other underlying conditions requiring specific treatment